Rameen Beroukhim, M.D., Ph.D., Dana-Farber Cancer Institute (IMAGE)

Dana-Farber Cancer Institute

Rameen Beroukhim, M.D., Ph.D., Dana-Farber Cancer Institute

Caption

Rameen Beroukhim, M.D., Ph.D., and his colleagues at Dana-Farber Cancer Institute and Broad Institute scientists report that large-scale genomic sequencing has revealed two DNA mutations that appear to drive about 15 percent of meningiomas. Experimental drugs that inhibit these mutant gene pathways are in clinical trials and have shown promising activity, suggesting that targeted therapies already in development or use may work against these specific meningiomas.

Credit

Sam Ogden

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.